Key Market Indicators
Hungarian antidepressant medicine sales are projected to fall to $19 million by 2028, down from $22 million in 2023. This represents an average annual decline of 2.5%. Since 2008, the Hungarian market has seen a consistent yearly decrease of 6%. In 2023, Hungary ranked 11th globally in antidepressant sales, with Finland surpassing it with sales also at $22 million. Spain, Italy, and Australia secured the 2nd, 3rd, and 4th positions respectively in the global ranking.
